Table 1.
Patient’s characteristics
Characteristic | |
---|---|
Age | |
median | 43.5 ans |
Range | 30-61 |
Hormone receptor status | |
positive | 17 (85%) |
negative | 3 (15%) |
HER2 status IHC : 3+ | 20 (100%) |
Nbre of metastatic sites | |
1 | 10 (50%) |
2 | 6 (30%) |
≥ 3 | 4(20%) |
Type of metastatic sites | |
Non visceral only | 5 (25%) |
Viscéral | 15 (75%) |
Liver | 6 (30%) |
Lung | 12 (60%) |
Brain | 1 (5%) |
Bone | 10 (50%) |
Skin | 2 (10%) |
Nodes | 6 (30%) |
Prior adjuvant chemotherapy | 16 (80%) |
Prior adjuvant hormonal therapy | 14 (70%) |
Adjuvant Trastuzumab | 0 (0%) |